Extended Data Fig. 9: Prognostic value of SPP1 (validation antibody HPA005562) or COL6A1 proteins in plasma and CSF of ALS patients.
From: Altered perivascular fibroblast activity precedes ALS disease onset
a, Relative levels of COL6A1 and SPP1 proteins in plasma, threshold selection and Kaplan-Meier survival estimates of ALS patients in discovery (n=452) and replication (n=122) cohorts. Red color indicates thresholded protein level. Thresholds are established using maximally selected log rank statistics. All boxplots show median, 2nd-3rd quartile and whiskers show ±1.5 of the IQR. COL6A1 protein values in the replication cohort did not indicate an optimized threshold and were separated at the median. Two-tailed Kaplan-Meier logrank test p-values. b, Cox proportional hazard models for continuous increase of SPP1 (HPA005562) and COL6A1 relative to hazard ratios indicated by gender, bulbar onset type plasma sampling age and cohort identity. Hazard ratios for Neurofilament light in CSF are indicated in the replication cohort. Whiskers represent 95% CI. c, Relative levels of SPP1 protein in CSF from the Swedish cohort from the two antibodies (HPA027541 and HPA005562). Threshold selection and Kaplan-Meier survival estimates of ALS patients. Two-tailed Kaplan-Meier logrank test p-values.
